News
VNDA
4.970
-5.15%
-0.270
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
NASDAQ · 15h ago
Deals of the day-Mergers and acquisitions
U.S. FTC preparing to sue to block Coach parent Tapestry's $8.5 billion deal to buy Michael Kors owner Capri. Zuora, Aurubis, Vanda Pharmaceuticals, TAQA, Royal Mail in talks to be sold.
Reuters · 1d ago
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
U.S. Stocks traded lower on Wednesday, with the Nasdaq Composite falling more than 100 points. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. European shares closed higher on Wednesday. In commodity news, oil traded down 3% to $82.78 and gold traded down 0.8%. U.s. Bancorp reported upbeat first-quarter FY24 earnings. Utilities shares rose by 1.5% on Wednesday after the company reported upbeat results.
Benzinga · 1d ago
Health Care Sector Update for 04/17/2024: VNDA, CLDX, NRBO
NASDAQ · 1d ago
Vanda Pharmaceuticals Up Over 30%, on Pace for Largest Percent Increase Since November 2013 -- Data Talk
Vanda Pharmaceuticals Inc. Is currently at $5.28, up $1.23 or 30.37%. Up 28.47% month-to-date, down 83.33% from its all-time closing high of $31.67 on Jan. 24, 2007.
Dow Jones · 1d ago
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
The Travelers Companies, Inc. Shares dipped 8.1% to $205.03 on Wednesday. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. InVO Bioscience shares shot up 256% after the company reported a year-over-year increase in fourth-quarter revenue.
Benzinga · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Outset Medical, Interactive Brokers, US energy sector
Wall Street's main indexes fell in choppy trading on Wednesday. The Dow Jones Industrial Average was down 0.05% and the S&P 500 and the Nasdaq Composite were both down. United Airlines Holdings was among the top percentage gainers. Downbeat earnings reports from some industry majors added to the losses.
Reuters · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.
Benzinga · 1d ago
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share
Vanda Pharmaceuticals Inc. Has received several unsolicited proposals from Future Pak LLC to acquire all of Vanda’s outstanding shares. The company says the offers significantly undervalue the company. The FDA approved Vanda's Fanapt tablets for the acute treatment of bipolar I disorder in adults.
Benzinga · 1d ago
BUZZ-Vanda Pharma rises after rejecting Future Pak's takeover proposal
Vanda Pharmaceuticals' shares jump 38.2% to $5.59 after rejecting takeover proposal from Future Pak. Company says it has adopted shareholder rights plan to reduce likelihood of hostile takeover. Future Pak's offer implies premium of 79% to 92% to Vanda's last close of $4.05.
Reuters · 1d ago
Vanda Pharma Adopts Limited Duration Stockholder Rights Plan; Stock Up
NASDAQ · 1d ago
Vanda Pharma Adopts Stockholder Rights Plan After Unsolicited Offers
Vanda Pharmaceuticals said its board of directors has adopted a limited duration stockholder rights plan. The stock is trading 38% higher, at $5.58, but is still down 14% in the past 12 months. The company said it has rejected multiple unsolicited offers to buy the company.
Dow Jones · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Children's Place, Travelers, First Horizon
Wall Street's main indexes rose on Wednesday. The Dow Jones Industrial Average .DJI was up 0.17% at 37,862.55. United Airlines Holdings was among the top percentage gainers. Children's Place, Travelers and First Horizon were among the biggest decliners.
Reuters · 1d ago
Vanda Pharmaceuticals Adopts 1-Year Term Limited Duration Stockholder Rights Plan To Protect Stockholder Interests And Maximize Value For All Stockholders, Effective Immediately
Vanda Pharmaceuticals Inc. Has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders. The Board adopted the Rights Plan in response to the unsolicited acquisition proposal made by Future Pak, LLC on April 1, 2024. The Rights Plan is effective immediately.
Benzinga · 1d ago
VANDA PHARMACEUTICALS INC - RIGHTS PLAN HAS A ONE-YEAR TERM, EXPIRING ON APRIL 16, 202
Reuters · 1d ago
Vanda Pharma Shares Rise 27% After Rejecting Unsolicited Offers
Vanda Pharmaceuticals shares were up 27% to $5.13. The company said it has rejected multiple unsolicited proposals from Future Pak. The stock is down 21% in the past 12 months. Future Pak has made several offers to buy all of Vanda's shares.
Dow Jones · 1d ago
Lexaria Bioscience, Biosig Technologies, BIMI Holdings among healthcare movers
Healthcare On the Move: Lexaria Bioscience, Biosig Technologies, BIMI Holdings among healthcare movers. S&P 500 Health Care Sector +0.35% to 1621.82. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 1d ago
VANDA PHARMACEUTICALS SHARES UP 30.4%; CO REJECTS TAKEOVER PROPOSAL FROM FUTURE PAK
Reuters · 1d ago
UPDATE 3-Vanda adopts 'poison pill' after rejecting Future Pak's offer
Vanda Pharmaceuticals rejects takeover proposal from Future Pak. Shares of Washington, DC-based drugmaker jump 37.78% to $5.58. The company has adopted a shareholder rights plan to reduce the likelihood of a hostile takeover. Future Pak's offer represents a 79-92% premium to the company's share price.
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Hasbro, Eli Lilly, Bloom Energy
Wall Street's main indexes eyed a higher open on Wednesday. Dow e-minis were up 0.19% in early trading. Top three NYSE percentage gainers premarket were VIA, United Airlines. Hasbro, Eli Lilly and Bloom Energy were up.
Reuters · 1d ago
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).